Avacta appoints david liebowitz, m.d., ph.d. as chief medical officer and yulii bogatyrenko as advisor in business development

London and philadelphia, july 01, 2025 (globe newswire) -- avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of david liebowitz, m.d., ph.d. as chief medical officer (cmo) and yulii bogatyrenko as an advisor in business development.

INO Ratings Summary

INO Quant Ranking